Organon wins FDA approvals expanding use of Actemra biosimilar Tofidence

Organon (NYSE:OGN) announced that the US Food and Drug Administration (FDA) has approved its supplemental Biologics License Application (sBLA) for Tofidence, expanding the therapeutic indications of the drug within the competitive US biosimilars market.

The approval broadens the administration of Tofidence, an intravenous injection that serves as a highly similar version of Genentech's blockbuster reference biologic, Actemra.

Under the newly sanctioned labels, the drug can now be utilized to treat severe or life-threatening cytokine release syndrome (CRS)—a volatile immune system reaction often induced by chimeric antigen receptor (CAR) T-cell cancer therapies—in both adult and pediatric patients aged two years and older.

Additionally, the label extension covers hospitalized adult and pediatric patients suffering from severe cases of COVID-19 who require advanced respiratory support, such as mechanical ventilation, supplemental oxygen, or extracorporeal membrane oxygenation (ECMO).

Organon executives noted that widening the clinical utility of the drug aims to reduce financial pressures on the healthcare system by providing low-cost alternatives to expensive, branded biological therapies.

Originally launched in May 2024, Tofidence holds the distinction of being the first approved tocilizumab biosimilar entrant in the United States.

Its existing core indications already include the long-term management of moderately to severely active rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.